AAO 2024: New gene therapy shows promise for treatment of …
Oct 20, 2024 · New research unveiled today at the 128th annual meeting of the American Academy of Ophthalmology in Chicago reveals that a novel gene therapy may improve vision in individuals with severe vision loss due to retinitis pigmentosa, a progressive inherited retinal disease for which no cure exists.
Ophthalmology Times - Ophthalmology news, articles, and events
A team of researchers in China detail a case of Thelazia callipaeda infection in the right eye of a 41-year-old woman working in an office. The patient presented with persistent foreign body sensation, pruritus, and redness despite initial treatment with …
Johnson & Johnson launches TECNIS Odyssey IOL in US
Oct 1, 2024 · Johnson & Johnson is expanding the launch of its presbyopia-correcting intraocular lense (IOL), TECNIS Odyssey, in the US.. The TECNIS Odyssey IOL is a new full vision range IOL, built on the TECNIS platform from Johnson & Johnson, which according to the company provides two times better contrast in low lighting than PanOptix. 1 Peter Menziuso, company group chairman, Vision, Johnson & Johnson ...
AAO 2024: Long-term low-dose antiviral treatment benefits …
Oct 19, 2024 · Long-term, low-dose antiviral treatment reduces the risk for potentially vision-damaging bouts of inflammation and infection, as well as pain, which occur when shingles affect the eye, according to new research presented October 19 at the American Academy of Ophthalmology’s (AAO) annual meeting in Chicago.
ASCRS 2024: What advancements in Light Adjustable Lens …
Apr 10, 2024 · Neda Nikpoor, MD, spoke to Ophthalmology Times about her presentation on the Light Adjustable Lens during an ASCRS symposia on IOL calculations.. Video Transcript. Editor's note - The following transcript has been lightly edited for clarity.. Neda Nikpoor, MD: Hi, my name is Neda Nikpoor.I am a private practice doctor—a cornea, cataract, and refractive surgeon in Honolulu, Hawaii.
Study suggests potential link between semaglutide and risk of non ...
Jul 9, 2024 · Boston researchers led by first author Jimena Tatiana Hathaway, MD, MPH, reported that there is a potential risk of the development of non-arteritic ischemic optic neuropathy (NAION) 1 associated with prescriptions for semaglutide (Wegovy, Ozempic, Novo Nordisk). Prescriptions with semaglutide are FDA approved to treat obesity and type 2 diabetes, respectively.
Physicians sort out pros and cons of several new IOLs on the market
Nov 12, 2021 · Monofocal IOLs The monofocal category was expanded recently with 2 novel aspheric hydrophobic acrylic lenses—the TECNIS Eyhance (ICB00, Johnson + Johnson Vision) and the Clareon (Alcon). The Eyhance IOL has extended depth of focus (EDoF)-like qualities through the design of the central 1 mm of its optic. However, the Eyhance was not approved as an EDoF lens and surgeons cannot charge a ...
Intense pulsed light for treatment of dry eye disease
Oct 31, 2024 · Joanne F. Shen, MD, director of the dry eye clinic at Mayo Clinic's campus in Phoenix, Arizona, and a research team studied 35 patients treated with IPL/MGX. The team reviewed demographics, ocular histories, Standard Patient Evaluation of Eye Dryness 2 symptom survey scores, slit-lamp examinations and meibomian gland evaluations at baseline and at each visit before IPL/MGX treatments.
FDA approves Bausch + Lomb’s enVista Envy range of IOLs
Oct 14, 2024 · According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets.
Teprotumumab: TED treatment shows benefits for patients
Nov 18, 2024 · References: Ugradar S, Parunakian E, Malkhasyan E, et al. The rate of re-treatment in patients treated with teprotumumab: a multicenter study of 119 patients with 1 year of follow up.